Jonathan M. Gerber, MD, PhD

Maintenance therapy with eprenetapopt plus azacitidine after hematopoietic stem cell transplantation led to improved survival outcomes among patients with TP53-mutant acute myeloid leukemia or myelodysplastic syndrome, study results showed.

Ficlatuzumab plus single-agent chemotherapy showed encouraging efficacy and appeared safe among patients with relapsed or refractory acute myeloid leukemia, according to phase 1 study results published in Blood Cancer Discovery.

Healio spoke with Jonathan M. Gerber, MD, of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, and HemOnc Today Editorial Board member, about the clinical implications of the BEAT-AML trial and genetic testing in AML.

Healio spoke with Jonathan M. Gerber, MD, of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, and HemOnc Today Editorial Board member, about the transition of newer agents into clinical practice.

Healio spoke with Jonathan M. Gerber, MD, chief of hematology-oncology and medical director of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, Eleanor Eustis Farrington Chair in Cancer Research and HemOnc Today Editorial Board member, about FDA approvals, the transition of newer agents into clinical practice and breakthroughs in therapy that he hopes to see in the future in this video series.

Healio spoke with Jonathan M. Gerber, MD, of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, and HemOnc Today Editorial Board member, about breakthroughs in therapy that he hopes to see in the future.

Healio spoke with Jonathan M. Gerber, MD, of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, and HemOnc Today Editorial Board member, about the underrecognized burden of high treatment costs in AML.

Ponatinib and blinatumomab induced high rates of complete molecular remission among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, according to research presented during the virtual ASCO Annual Meeting.

Ruxolitinib induced responses in about one-third of a cohort of patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia, according to results of a single-arm phase 2 study published in Journal of Clinical Oncology.

Patients with acute myeloid leukemia and adverse-risk cytogenetics had an unfavorable prognosis regardless of whether they harbored mutated or wild-type NPM1, according to results of a pooled analysis of patient data published in Journal of Clinical Oncology.